Adiponectin KO (Adipoq / ) (B6;129-Adipoqtm1Chan/J), UCP1 KO (UCP1 / ) (B6.129- Ucp1 tm1Kz /J) mice and their respective wild type controls were purchased from the Jackson Laboratory
Badaracco said labels should instead focus on how products will benefit consumers
SGLT2 inhibitors, such as empagliflozin and canagliflozin, have similar A1C-lowering properties (0.5%-0.8%) and out-of-pocket costs (except for alogliptin, which is available generically), but have the added advantages of CV risk reduction, BP-lowering, and weight loss
Increased heart rate is the most common cardiovascular effect, followed by elevated blood pressure
Disclosures: Majd Aboona: Nothing to Disclose, Leith Ghani: Nothing to Disclose, Pooja Rangan: Nothing to Disclose, Vincent Chen: AstraZeneca: site PI on industry-sponsored trial, Ipsen: site co-I on industry-sponsored trial, Kowa: site co-I on industry-sponsored trial, Cheng Han Ng: Nothing to Disclose, Daniel Huang: Nothing to Disclose, Mark Muthiah: Lerna Bio: Stock privately held company, Olympus: Speaking and Teaching, Boston Scientific: Speaking and Teaching, Novo Nordisk: Grant/Research Support, Echosens: Grant/Research Support, Gilead: Advisor, Donghee Kim: Nothing to Disclose, Moises Nevah Rubin: Nothing to Disclose, Ma Ai Thanda Han: Nothing to Disclose, Michael Fallon: Nothing to Disclose, Karn Wijarnpreecha: Nothing to Disclose 1123 RISK OF COMORBID MENTAL HEALTH CONDITIONS IN CHILDREN WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Sheila Noon 1 Nhat Thai 2 Kimberly Newton 3 Nidhi Goyal 3 Benjamin Maxwell 3 Elizabeth Yu 3 Warren Shapiro 4 Jeffrey Schwimmer 3 , 1 University of California, San Diego School of Medicine, 2 San Diego State University, 3 Rady Children's Hospital San Diego, 4 Kaiser Permanente San Diego Background: Steatotic liver disease (SLD) affects nearly 1 in 10 children in the United States
Funding This work was supported by the Natural Science Foundation of China (No
